Prevention, testing, and treatment interventions for hepatitis B and C in refugee populations: results of a scoping review.  Saseetharran A, Hiebert L, Gupta N, Nyirahabihirwe F, Kamali I, Ward JW.  BMC Infect Dis. 2023 Dec 9;23(1):866…

Hepatitis C in Europa unterschiedlich weit verbreitet Stockholm – Im Europäischen Wirtschaftsraum (EU/EAA) sind etwa 1,8 Millionen Menschen mit Hepatitis C infiziert, wobei die Prävalenz in Süd- und vor allem Osteuropa deutlich höher ist. Fast ein…

EMCDDA. Viral hepatitis elimination barometer among people who inject drugs in Europe About the elimination barometer The elimination barometer for hepatitis B and C among people who inject drugs is designed to support countries affiliated to the…

HIV, hepatitis & drug policy reform This report, “HIV, Hepatitis & Drug Policy Reform” follows the Global Commission’s thematic reports on “The War on Drugs and HIV/AIDS” (2012) and “The Negative Impact of the War on Drugs on Public Health…

A decade of HCV drugs The FDA’s approval of Gilead’s hepatitis C virus (HCV) drug sofosbuvir (Sovaldi) in December 2013 made big healthcare waves. Drug developers heralded the long-awaited arrival of a wonder drug that promised to wipe out a previo…

Novel therapies for hepatitis C — one pill fits all? Manns, M., von Hahn, T.  Nat Rev Drug Discov 12, 595–610 (2013). doi.org/10.1038/nrd4050 https://www.nature.com/articles/nrd4050